Sorry, I wasn't trying to imply that they should ramp up production. I have a hazy memory of someone on this board saying that they had done so before the CRL. I'm not making a judgement on whether that was the right thing to do or not. I am just trying to make some guesses on the number of patients that could be treated immediately if RemL was approved.
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-431
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |